 |
 |
|
|
 |
RTI-HS Home
Our Services
Patient-Reported Outcomes
Patient-Reported Outcomes
Making sure the voice of the patient is heard
Our multidisciplinary PRO team can help you assess the impact of diseases on patients and demonstrate the drug benefits most important to them.
We work collaboratively with our clients to provide payers, providers, and regulators with a better understanding of the patient experience.
Core Services PRO fact sheet
Development and Support of PRO Measurement Strategies
- Literature and instrument reviews
- Gap analysis
- Clinical trial design
- Utility studies
Instrument Development, Modification, and Adaptation
- Focus groups and in-depth interviews
- Cognitive debriefing
- Item development and modification
- Cross-cultural adaptation
Psychometric Evaluation Psychometrics fact sheet
- Classical methods
- Item response theory (IRT)
- Data collection (independent from clinical trials)
Regulatory Guidance and Support
- Negotiations with FDA and EMA
- PRO Dossiers
Market Research
- Qualitative research
- Surveys
- Sensory panels
Why Choose Our PRO Team?
Strong, multidisciplinary team
- 25 PRO specialists in the US and Europe
- All have advanced academic degrees and significant industry experience
- Collectively conducted thousands of successful PRO projects across therapeutic areas
FDA Experience
- Strong understanding of the FDA's requirements for the support of labeling claims
- Extensive experience with various reviewing divisions and the Study Endpoints and Label Development (SEALD) team
EMA Experience
- Significant experience liaising with the EMA to negotiate the acceptability of PRO endpoints
- Routinely guide industry clients through the EMA's PRO Scientific Advice and Biomarker qualification processes
Related Services
For your projects that may have cross-functional requirements, we also offer the following complementary services:
|
|
 |
 |
 |
| |
CONTACT US
|
| |
US: +1.800.262.3011
Spain: +34.93.241.7766
UK: +44(0)161.232.3400
For a full list of scientific staff bios, click here.
|
|
| |
|
|
|
 |
|